Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology

Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: Expert group on behalf of the indian academy of neurology

Sruthi S Nair, Lekha Pandit, Thomas Mathew, Salil Gupta, Gagandeep Singh, Bhatia Rohit, Bhim S Singhal, Dheeraj Khurana, M.V. Padma Srivastava, M Netravathi

Knowledge related to SARS-CoV-2 or 2019 novel coronavirus (2019-nCoV) is still emerging and rapidly evolving. We know little about the effects of this novel coronavirus on various body systems and its behaviour among patients with underlying neurological conditions, especially those on immunomodulatory medications. The aim of the present consensus expert opinion document is to appraise the potential concerns when managing our patients with underlying CNS autoimmune demyelinating disorders during the current COVID-19 pandemic.

2020

immunotherapy, MS, disease modifying therapy, MOG, NMOSD, COVID-19

DOI: 10.4103/aian.AIAN_259_20

Annals of Indian Academy of Neurology

Wolters Kluwer Medknow Publications

Neurology. Diseases of the nervous system